GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs
Kailera Therapeutics and Alamar Biosciences have filed for U.S. IPOs. Kailera, focused on weight loss drugs, plans to list on Nasdaq under "KLRA" with its lead candidate, ribupatide, in Phase 3 trials. The company reported a $149M net loss in 2025. Alamar, specializing in proteomics, aims to list under "ALMR" and reported $74.2M revenue in 2025, with a narrowed net loss of $29.8M. Both companies are seeking to raise capital through their IPOs.
Source: businessinsider The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments